You are here: Home / Central Office (Cordoba Unit) / ADMINISTRATIVE UNIT / León S. Morra: List of Essential Publications
Monday, 25.09.2017

León S. Morra: List of Essential Publications

            We are preparing a chronological list of essential publications and we are inviting you to participate in the creation of this list as contributor, advisor or co-author of the final list that will be presented by INHN Education in the form of an E-Book.

To provide orientation points for preparing such a list, Tom Ban extracted 330 publications (shortlist), from the over 1500 publications he listed in chronology as an Appendix to volume 10 of ACNP’s An Oral History of Neuropsychopharmacology (see “short list” below).  

To become a “contributor” to INHN’s List of Essential Publications, you will be expected to suggest 10 or more publications for consideration to be entered on the “short list” and to become an “advisor” you will be expected to suggest 10 or more publications for consideration to be entered on and 10 or more publications for consideration to be deleted from the “short list”. To become “co-editor” of the E-Book, you will be expected to participate in addition in the creation of the final product.

Regardless of whether your suggestions to add or delete from the “short list” will be accepted, your suggestions will be posted in your Collection in Archives.  

Chronological List of Publications

Short List

1.      Sertűrner FW. Darstellung der reinen Mohnsäure (Opiumsäure) nebst einer Chemischen Untersuchung des Opiums mit vorzűglicher Hinsicht auf einen darin neu entdecten Stoff und dahin gehörigen Bemerkungen. Journal der Pharmacie fűr Ärzten und Apotheken (Leipzig) 1806; 14: 47–93.

2.      Liebig J. Über die Verbindungen welche durch die Einwirkung des Chlors auf Alcohol, Aether, Oilbildendes Gas und Effiggeist Entstehen. Liebigs Annalen der Pharmazie 1832; 1: 182–230.

3.      Moreau de Tours J. Du Hachich et de L’Aliénation Mentale. Etudes Psychologiques. Paris: Fortin & Masson; 1845.

4.       Bernard C. Introduction a l’étude de la médicine expérimentale. Paris: Baillière; 1865.

5.      Liebreich MEP. Das Chloralhydrate, ein neues Hypnoticum und Anaestheticum, und dessen Anwendung in die Medizin. Eine Arzneimittel-Untersuchung. Berlin: Müller; 1869.

6.      Wernicke C. Die acute hemorrhagische Poliencephalitis superior. In: Wernicke C. Lehrbuch der Gehirnkrankheiten fűr Ärzte und Studierende. Bd II. Kassel: Fischer; 1881. p. 1176-8.

7.      Cervello V. Über die Physiologische Wirkung des Paraldehyds und Beiträge zu den Studien über das Chloralhydrate. Arch Exp Path Pharmacol 1882; 16: 265–90.

8.      Freud S. Über Coca. Centralblatt fűr die ges Therapie 1884; 2: 289-314.

9.      Lange C. Om Periodiske Depressionstilstande ofderes Patogenese. Copenhagen: Jacob Lunds Forlag; 1886.

10.  Edeleano L. Ueber einige Derivate der Phenylmethacrylsäure und der Phenylbuttersäure. Berl Deutsch Chem Ges 1887; 20: 616-22.

11.  Korsakoff SS. Disturbances of psychic functions in alcoholic paralysis in relation to the disturbances of the psychic structure in multiple neuritis of non-alcoholic in origin.  Vestnik klinicheskoi i sudebnoi psikhiatrii i nevropatologii (St. Petersburg) 1887; 4: 1-102. (In Russian).

12.  Kraepelin E. Über die Beeinflussung einfacher psychischer Vorgänge durch einige Arzneimittel. Jena: Fischer; 1892.

13.  Fischer E, Mering von J. Über eine neue Klasse von Schlafmittels. Ther Ggw 1903; 44: 97–101.

14.  Bonhoeffer K. Zur Frage der exogenen Psychosen. Neur Zlb 1909; 32: 499-505.

15.  Knauer A, Maloney WM. Psychic action of mescaline.  J Nerv Ment Dis  1913; 40: 425-40..

16.  Alles GA. The comparative physiological action of phenylethanolamine. J Pharmacol 1927; 32: 121–33.

17.  Beringer K. Mescaline Intoxication. Berlin: Springer; 1927.

18.  Lewin L. Phantastica: Narcotic and Stimulating Drugs. Their Use and Abuse. London: Routledge; 1931.

19.  Fölling A. Phenylketonuria. Nord med Tdsk 1934; 8: 1054-8.

20.  Noteboom L. Experimental catatonia by means of derivatives of mescaline and adrenaline. Proc Natl Acad Sci USA 1934; 37: 562–3.

21.  Gantt WH. Effect of alcohol on cortical and subcortical activity measured by the conditional reflex method.  Bull. Johns Hopkins Hosp 1935; 56: 61–83.66

22.  Prinzmetal M, Blumberg W. The use of Benzedrine in the treatment of narcolepsy. JAMA 1935; 105: 2051–3.

23.  Thorner NW. Psychopharmacolgy of sodium amytal. I. Catatonia. J Nerv Ment Dis 1935; 82: 299–303.66.

24.  Blaschko H, Richter D, Schlossman H. The oxidation of adrenaline and other amines. Biochem J 1937; 31: 2187-96.

25.  Bradley CB. The behavior of children receiving Benzedrine. Am J Psychiatry 1937; 94; 577-80.

26.  Elvehjem CA, Madden RJ, Strong FM, Woolley DW. The isolation and the identification of the anti-blacktongue factor. J Biol Chem 1937; 123: 137–49.

27.  Fouts PJ, Helmer OM, Lepkovsky YS, Jukes TH. Treatment of human pellagra with nicotinic acid. Proc Soc Exp Biol Med 1937; 37: 405–7.

28.  Stedman E, Stedman F. Mechanism of biological synthesis of acetylcholine: isolation of acetylcholine produced by brain tissue in vitro. Biochem J 1937; 31: 817-20.

29.  Zeller EA. Über den enzymatischen Abbau von Histamin und Diaminen. Helvetia Chem Acta 1938; 21: 881-90.

30.  Bender L, Cottington F. The use of amphetamine sulfate (Benzedrine) in child psychiatry. Amer J Psychiatry 1942; 99: 116-21.

31.   Stokes JH, Sternberg TH, Schwartz WH, Mahoney JF, Moore JE, Wood WB. The action of penicillin in late syphilis including neurosyphilis. JAMA 1944; 126: 73–9.

32.  Von Euler US. A specific sympathomimetic ergone in adrenergic nerve fibers (sympathin) and its relation to adrenaline and noradrenaline. Acta Physiol Scand 1946; 12: 73.

33.  De Wardener HE, Lennox B. Cerebral beriberi (Wernicke’s encephalopathy): review of 52 cases in Singapore prisoner-of-war hospital. Lancet 1947; 1: 11–7.

34.  Stoll WA. Lysergic acid diethylamide, a “phantasticum” derived from the ergot group of drugs. Schweiz Arch Neurol Psychiat 1947; 60:279-80.

35.  Walker CF, Kirkpatrick BB. Dilantin treatment of behavior problem in children with abnormal EEGs.  Amer J Psychiatry 1947; 103: 484-92. 

36.  Hald J, Jacobsen E, Larsen V. The formation of acetaldehyde in the organism after the ingestion of Antabuse (tetraethylthiuram disulphide) and alcohol. Acta Pharmacol et Toxicol 1948; 4: 285-311.

37.  Kety SS, Schmidt C. The nitrous oxide method for quantitative determination of cerebral blood flow in man: theory, procedure and normal values. J Clin Invest 1948; 27: 475–83.

38.  Kety SS, Woodford RB, Harmel MH, Freyhan F, Appel K, Schmidt C. Cerebral blood flow and metabolism in schizophrenia.The effects of barbiturates, semi-narcosis, insulin coma and electroshock. Am J Psychiatry 1948; 104: 765–70.

39.  Cade J. Lithium salts in the treatment of psychotic excitement.  Med J Aust. 1949; 2; 349-52. Dent JY. Apomorphine treatment of addiction. British Journal of Alcohol and Other Drugs 1949; 46: 15-28.

40.  Jacobsen E, Martensen-Larsen MD. Treatment of alcoholism with tetraethylthiuram disulphide. JAMA 1949: 134: 918-22.

41.  Awapara J, Landua AJ, Fuerst R, Seale B. Free γ-aminobutyric acid in brain. J Biol Chemistry 1950; 187: 35-9..

42.  Mayer-Gross W. Experimental psychosis and other mental abnormalities produced by drugs. Brit Med J 1951; 57: 317-21.

43.   Noack CH, Treutner EM. The lithium treatment of maniacal psychosis. Med J Aust 1951; 38: 219-22.

44.  Pasamanick B. Anticonvulsant drug therapy of behavior problem children with abnormal electroencephalogram.  AMA Arch Neurol & Psychiat 1951; 65: 752-66.

45.  Delay J, Deniker P. Le traitment des psychoses par une méthode neurolytique dérivée de l’hibernothérapie; le 4560 RP utilisée seul en cure prolongée et continué. CR Congr Méd Alién Neurol (France) 1952; 50: 497–502.

46.  Delay J, Deniker P. 38 cas de psychoses traitèes par la cure prolongée et continué de 4560 RP. CR Congr Méd Alién Neurol (France) 1952; 50: 503–13.

47.  Delay J, Deniker P. Réactions biologiques observées au cours du traitement par l’chlorhydrate de deméthylaminopropyl-N-chlorophénothiazine. CR Congr Méd Alién Neurol (France) 1952; 50: 514–8.

48.  Erspamer V, Asero B. Identification of enteramine, specific hormone of enterochromaffin cells as 5-hydroxtryptamine. Nature 1952; 169: 800-1.

49.  Flaherty JA. The psychiatric use of isonicotinic acid hydrazide: a case report. Del Med J 1952; 24: 298–300.

50.  Laborit H, Huguenard P, Alluaume R. Un nouveau stabilisateur végétatif (le 4560 RP). Presse Méd 1952; 60: 206–8.

51.  Műller JM, Schlittler E, Bein HJ. Reserpin der sedative wirkstoff aus Rauwolfia serpentine Benth. Experientia 1952; 8: 338–9.

52.  Selikoff IJ, Robitzek FH, Orenstein GG. Treatment of pulmonary tuberculosis with hydrazine derivatives of isonicotinic acid. JAMA 1952; 150: 973–80.

53.  Zeller EA, Barsky JR, Fouts W, Kirchheimer WP, Van Orden LS. Influence of isonicotinic acid hydrazide (INH) and 1-isonicotinyl-2-isopropyl hydrazide (IIH) on bacterial and mammalian enzymes. Experientia 1952; 8: 349–50

54.  .Bradley PB, Elkes J. The action of amphetamine  and D-lysergic acid diethylamide (LSD 25) on the electrical activity of the brain of the conscious cat. J Physiol (London) 1953; 120: 13–4.

55.  Delay J, Laine R, Buisson JF. Anxiety and depressive states treated with 1-isonicotinylhydrazide (isoniazid). Arch Neurol Psychiat 1953; 70: 317-24.

56.  Flűgel F. Neue klinische Beobachtungen zur Wirkung des Phenothiazinkorpere Megaphen auf psychische Krankheitsbilder. Medizinische Klinik 1953; 48; 1027-9.

57.  Fox HH, Gibbas JT. Synthetic tuberculostats.  VII. Monoalkyl derivatives of isonicotinylhydrazine J Org Chem 1953; 18: 992-1002.

58.  Gaddum JH. Antagonism between lysergic acid diethylamide and 5-hydrxytryptophan. J Physiol (London) 1953; 121: 15-8.

59.  Salter HM, Lurie ML. Anxiety and depressive states treated with isonicotinyl hydrazide (isoniazid). Arch Neurol Psychiatry 1953; 70: 317–24.

60.  Seevers MH, Woods LA. The phenomena of tolerance. Am J Med 1953; 5: 546-57.

61.  Twarog BM, Page IH. Serotonin content of some mammalian tissues and urine and a method for its determination.  Am J Physiol 1953; 175: 157-61.

62.  Zeller G. Substance P in the central nervous system. Naturwissenschaften 1953; 40: 559-60.

63.  Amin AH, Crawford TB, Gaddum JH The distribution of substance P and 5- hydroxytryptamine in the central nervous system of the dog.  J Physiol 1954; 126: 596-618.

64.   Bente D, Itil TM. Zur Wirkung des Phenothiazin Körpers Megaphen und das menschliche Hirnstrombild.  Arzneimittel Forschung 1954; 4: 418-23.

65.  Berger FM. The pharmacodynamic properties of 2-methyl-2-n-1, 3 popanediol dicarbamate (Miltown), a new interneuronal blocking agent. J Pharmacol Exp Ther 1954; 112: 413-23.

66.  Bradley PB, Elkes J. The effects of some drugs on the electrical activity of the brain. Brain.  1954; 80: 77; 117-20.

67.  Delay J, Deniker P, Tardieu Y, Lemperière Th. Premiers essais en thérapeutique psychiatrique de la réserpine, alcaloide nouveau de la Rauwolfia Serpentina. CR Congr Méd Alién Neurol (France) 1954; 52: 836-41.

68.  Freis ED. Mental depression in hypertensive patients treated for long periods with large doses of reserpine. N Engl J Med 1954; 251: 1006-8.

69.  Gaddum JH, Hamead KA. Drugs which antagonize 5-hydroxytryptamine. Br J Phramacol 1954; 9: 240-8.

70.  Kline NS. Use of Rauwolfia serpentina Benth in neuropsychiatric conditions. Ann NY Acad Sci 1954; 59: 107-32.

71.  Lehmann HE, Hanrahan GE. Chlorpromazine, new inhibiting agent for psychomotor excitement and manic states. Arch Neurol Psychiatry 1954; 71: 227-37.

72.  Schou M, Juel-Nielsen N, Strömgren E, Voldby H. The treatment of manic psychosis by the administration of lithium salts. J Neurol Neurosurg Psychiatry 1954; 17: 250-60. 

73.  Steck H. Le syndrome extrapyramidal et diencéphalique au cours des traitements au Largactil et au Serpasil. Ann Med Psychol 1954; 112: 737-43.

74.   Vogt M. Concentration of sympathin in different parts of central nervous system under normal conditions and after administration of drugs. J Physiol 1954; 123: 451-81.

75.  Woolley DW, Shaw E. A biochemical and pharmacological suggestion about certain mental disorders. Proc Natl Acad Sci 1954; 40: 238-41

76.  Arnold OH, Hofmann G. Untersuchungen űber Bernsteinsäuere effekte bei LSD-25-Vergiftungen und Schizophrenia. Wien Z Nervenheilk 1955; 11: 92-3.

77.   Bowman RL, Caulfield PA, Udenfriend S. Spectrophotometric assay in the visible and ultraviolet. Science 1955; 122: 32-3.

78.  Brodie BB, Axelrod J, Cooper JR, Gillette L,  LaDu BN, Mitoma C, Udenfriend S. Detoxication of drugs and other  compounds by liver microsomes. Science 1955; 121: 603-4.

79.  Davies DL, Shepherd M. Reserpine in the treatment of anxious and depressed patients. Lancet 1955; 2: 117-20.

80.  Foster W, Schultz S, Henderson A. Combined hydrogenated alkaloids of ergot in senile and arteriosclerotic psychoses.  Geriatrics 1955; 10: 26-30.

81.  Hollister E. Combined hydrogenated alkaloids of ergot in mental and nervous disorders associated with old age. Dis Nerv Syst 1955; 16: 1-4.

82.  Hollister LE, Krieger GE, Kringel A, Roberts RH. Treatment of schizophrenic reactions with reserpine. NY Acad Sci 1955; 61: 92-100.

83.   Lasagna L. The controlled clinical trial. Theory and Practice 1955; 1: 353-67.

84.  Lombard JP, Gilbert JG, Donofrio AF. The effect of glutamic acid upon the intelligence, social maturity and adjustment of a group of mentally retarded children.  Amer J Ment Def 1955; 60: 122-32.

85.  Pletscher A, Shore PA, Brodie BB. Serotonin release as a possible mechanism of serotonin action. Science 1955; 122: 374-5

86.  Salzer HM, Lurie ML. Depressive states treated with isonicotinyl hydrazide (isoniazid). Ohio State Med J 1955; 51:437–41.

87.  Woolf LL, Griffiths R, Moncrieff A. Treatment of phenylketonuria with a diet low in phenylalanine. Brit med J 1955; 7: 57-64.

88.  Zahn L. Erfahrungen mit einem zentralen Stimulans (Ritalin) bei cerebralen Altersveränderungen. Berl Gesundheitsblatt 1955; 6: 419-20.

89.  Besendorf H, Pletscher A. Beeinflussung zentraler Wirkungen von Reserpin und 5-Hydroxytryptamin durch Isonikotinsäurehydrazide. Helv Physiol Pharmacol Acta 1956; 14: 383-90.

90.  Brady JV. Assessment of drug effects on emotional behavior. Science 1956; 123: 1033-4.

91.  Brodie BB, Shore PA, Pletscher A. Limitation of serotonin releasing activity to those alkaloids possessing tranquilizing action. Science 1956; 123: 992-3.

92.  de Boor W. Psychopharmakologie und Psychopathologie. Berlin: Springer; 1956. p. 1-291.

93.  Gershon S, Trautner EM. Treatment of shock dependency by pharmacological agents. Med J Aust 1956; 43: 783-7.

94.  Gyermek L, Lázár GT, Csák Zs. The antiserotonin action of chlorpromazine and some other phenothiazine derivatives.  Arch Int Pharacodyn 1956; 107: 62-74.

95.  Holzbauer M, Vogt M. Depression by reserpine of the noradrenaline concentration in the hypothalamus of the rat. J Neurochem 1956; 1: 8-11

96.   Lyttle GG. Apomorphine treatment of alcoholism. Brit Med J 1956; 2: 1056-7.

97.   Olds J, Killam KF, Bachy-Rita F. Self-stimulation of the brain used as a screening method for tranquilizing drugs. Science; 1956; 124: 265-6.

98.   Pletscher A. Beeinflussung des 5-Hydroxytryptamin-stoffwechsels im Gehirn durch Isonikotinsäurehydrazide. Experientia 1956; 12: 479–80.

99.   Pletscher A, Shore PA, Brodie BB. Serotonin as a modulator of reserpine action in brain. J Pharmacol Exper Ther 1956; 116: 84-9.

100.Szára S. Dimethyltryptamine: its metabolism in man; the relation of its psychotic effect to serotonin metabolism. Experientia 1956; 12: 441-2.

101.Arnold OH, Hofmann G. Zur Psychopathologie des Dimethyltryptamin. Wien Z Nervenheilk 1957; 13: 438-45.

102.Bradley PB, Elkes J. The effects of some drugs on the electrical activity of the brain. Brain 1957; 80: 77-117.

103.Brill H, Patton RE. Analysis of 1955-56 population fall in New York State Mental Hospitals in the first year of large-scale use of tranquilizing drugs. Am J Psychiatry 1957; 114: 509 – 17.

104.Cook L, Wesley E. Behavioral effects of some psychopharmacological agents. Ann NY Acad` Sci 1957; 66:740–52.

105.Crane GE. Iproniazid (Marsilid) phosphate a therapeutic agent for mental disorders. Psychiatr Res Reports 1957; 8: 142-54. .

106.Gaddum JH. Serotonin-LSD interaction. Annals of the New York Academy of Sciences 1957; 66: 643-8.

107.Gerard RW. Drugs for the soul; the rise of psychopharmacology. Science 1957; 125: 201-3

108. Kuhn R. Über die Behandlung depressives Zustande mit einem iminodibenzyl-derivat (G22355). Schweiz Med Wochenschr 1957; 87: 1135-40.

109.Loomer HP, Sanders JC, Kline NS. A clinical and pharmacodynamic evaluation of iproniazid as a psychic energizer. Psychiatr Res Rep Am Psychiatr Assoc 1957; 8: 129-41.

110.Montagu KA. Catechol compounds in rat tissues and in brains of different animals. Nature 1957; 180: 240-1.

111.Pletscher A. Release of 5-hydroxytryptamine by benzoquinolizine derivatives with sedative action. Science 1957; 126: 507-8.

112.Wikler A. The Relation of Psychiatry to Pharmacology. Baltimore: Williams and Wilkins; 1957.

113.Bradley PB. The.central action of certain drugs in relation to the reticular formation of the brain. In: Jasper HH, Proctor LD, Knighton RS, Noshay WC, Costello RT, editors. Reticular Formation of the Brain. Boston: Little Brown & Company; 1958. p. 123–49.

114.Bradley PB, Key BJ. The effect of drugs on arousal responses` produced by electrical stimulation of the reticular formation of the brain. Electroencephalog Clin Neurophysiol 1958; 10: 97-110.

115.Bradley PB, Mollica A. The effect of adrenaline and acetylcholine on single unit activity in the reticular formation of the decerebrate cat. Arch Ital Biol 1958; 96: 168–86.

116.Brodie BB, Maickel RP. Termination of drug metabolism.  Federation Proceedings 1958; 17: 1163-4.

117.Carlsson A, Lindquist M, Magnusson T, Waldeck B. On the presence of 3-hydroxytyramine in brain. Science 1958; 127: 471-2.

118. Connell PH. Amphetamine Psychoses. London: Chapman and Hall; 1958.

119.Hofmann A, Heim R, Brack A, Kobel H. Psilocybin, ein psychotroper Wirkstuff aus dem mexikanischen Rauchpilz Psilocybe Mexicana  Heim. Experientia 1958; 14: 107-9.

120.Lehmann HE, Cahn CH, deVerteuil R. Treatment of depressive conditions with imipramine (G-22355). Can Psychiatr Assoc J 1958; 3: 155-64.

121.Olds J, Olds ME. Positive reinforcement produced by stimulating hypothalamus with iproniazid  and other compoudns. Science  1958; 127: 1175

122.Axelrod J. The metabolism of catecholamines in vivo and in vitro. Pharmacol Rev 1959; 11: 402-8.

123.Bertler A, Rosengren E.  Occurrence and distribution of dopamine in brain and other tissues.  Experientia 1959; 15: 10-1.

124. Brady JV. Comparative psychopharmacology: animal experimental studies on the effects of drugs on behavior. In: Cole JO, Gerard RW, editors. Psychopharmacology Problems in Evaluation. Washington: National Academy of Sciences - National Research Council; 1959. p. 46-63. 

125. Domenjoz R, Theobald W. Zur Pharmacolgie des Tofranil. Arch Int Pharmacodyn 1959; 120: 450-89.

126.Fink M. EEG and behavioral effects of psychopharmacological agents. In: Bradley PB, Deniker P, RadoucoThomas C, editors. Neuropsychopharmacology. Proceedings of the First International Congress of Neuropharmacology. Amsterdam/London: Elsevier Publishing Company; 1959. p. 442-6.

127.Freyhan F. Selection of patients from the clinical point of view. In: Cole JO, Gerard RW, editors.  Psychopharmacology. Problems in Evaluation. Washington: National Academy of Sciences – National Research Council; 1959. p. 372-89.

128.Kral VA, Wigdor BT. Androgen effect on senescent memory function. Geriatrics 1959; 14: 450-6.

129.Lambert P, Perrin J, Revol L, Achaintre A, Balvet P, Beaujard M, Berthier C, Broussolle P, Requet A. Essai de classificationd’apres`leurs activités psychpoharmacologiques et cliniques. In: Bradley PB, Deniker P, Radouco-Thomas C, editors. Neuropsychopharmacology. Amsterdam/London/New York/Princeton: Elsevier Publishing Company; 1959. p. 619-24.

130.Luby ED, Cohen BD, Rosenbaum G, Gottlieb JS, Kelley R.  Study of a new schziophrenomimetic drug - Sernyl. AMA Arch Neurol Psychiat 1959; 81: 363-9.

131.Meduna LJ, Abood LG. Studies of a new drug (Ditran) in depressive states. J Neuropsychiat 1959; 1: 20-22.

132.Pare CMB, Sandler M A clinical and biochemical study of a trial of iproniazid in the treatment of depression. J  Nerol Neurosurg Psychiat  1959;  22: 247-51.

133.West ED, Dally PJ. Effects of iproniazid in depressive syndromes. Br Med J  1959; 1: 1491-99.

134.Zimmerman HJ, Rosenblum L, Korn J, Feldman PE. Some preliminary clinical and biochemical aspect of liver function in patients receiving iproniazid. Annals of the New York Academy of Science 1959; 80: 915-27.

135.Aschcroft GW, Sharman DF. 5-Hydroxyindoles in human cerebrospinal fluid.  Nature 1960; 186: 1050-1.

136.Ayd FJ. Amitriptyline (Elavil) therapy of depressive reactions. Psychsomatics 1960; 1: 320–5.

137.Costa E, Garattini S, Valzelli L. Interaction between reserpine, chlorpromazine and imipramine. Experientia 1960; 15: 461-3.

138.Gershon S, Olariu J. JB-329, a new psychotomimetic, its antagonism by tetrahydro-aminoacridane and its comparison with LSD, mescaline, and Sernyl. J Neuropsychiatry 1960; 1: 283–9.

139.Gershon S, Yuwiler A. Lithium ion: A specific psychopharmacological approach to the treatment of mania. J Neuropsychiat 1960; 1: 229–41.

140.Gyermek L, Posemanto C. Potentiation of 5-hydroxytryptamine by imipramine. Medicina Exper 1960; 3: 225-9.

141.Hollister LE, Glazener FS. Withdrawal reactions  from meprobamate alone and combined with promazine: A controlled study. Psychopharmacologia 1960; 1: 336-41.

142.Adler MW. Changes in sensitivity to amphetamine in rats with chronic brain lesions. The Journal of Pharmacology 1961;134: 214-21

143.Axelrod J, Whitby LB, Hertting G. Effect of psychotropic drugs on the uptake of 3H- norepinephrine by tissues. Science 1961; 133: 383-4.

144.Ban TA, Lohrenz JJ, Lehmann HE. Observations on the action of Sernyl - A new psychotropic drug. Can Psychiat Assoc J 1961; 6: 150-7.

145.Brodie BB, Dick P, Kielholz P, Pöldinger W, Theobald W. Preliminary pharmacological and clinical  results with desmethylimipramine (DMI) G 35020, a metabolite of Tofranil. Psychopharmacologia 1961; 19: 46-74.

146.Freyhan F. The influence of specific and non-specific factors on the clinical effects of psychotropic drugs. In: Rothlin E, editor. Neuropsychopharmacology.. Amsterdam/London/New York/Princeton: Elsevier Publishing Company; 1961. p. 189-203

147.Gilette JR, Dingell JV, Sulser F, Kuntzman R, Brodie BB. Isolation from rat brain of a metabolic product desmethylmipramine (DM) G35020, a metabolite of imipramine. Psychopharmacologia 1961; 19: 467-74.

148.Hertting G, Axelrod J, Whitby LC. Effect of drugs on the uptake and metabolism  of [3H] norepinephrine. J Pharmacol Exp Ther 1961; 134: 146-53

149.Hertting G, Axelrod J, Kopin IJ, Whitby LG. Lack of uptake of catecholamines after  denervation of sympathetic nerves. Nature 1961; 189: 66-7.

150.Hollister LE, Montzenbecker PP, Degan RO. Withdrawal reaction from chlordiazepoxide (Librium). Psychopharmacologia 1961; 2: 63-8.

151.Holmberg G, Gershon S. Autonomic and psychic effects of yohimbine hydrochloride 1961; 2: 93-106

152.Itil TM. Elektroenzephalographische Befunde zur Klassifikation neuro- und thymoleptischer  Medikamente. Med Exp 1961; 5: 347-63.

153.Selbach H. Über die vegetative Dynamik in der psychiatrischen Pharmkotherapie. Dtsch med Wschr 1961; 12: 511-7.

154.  Dingell JV, Sulser F, Gillette JR. Metabolism of imipramine  in rats and rabbits. Fed Proc 1962; 21: 184-5.

155.Falck B, Hillarp N-Ǻ, Thieme G, Torp A. Fluorescence of catecholamines and related compounds condensed with formaldehyde. J Histochem Cytochem 1962; 10: 348-54.

156.Gibbons JL, McHugh PR. Plasma cortisol in depressive illness.  J Psychiatr Res 1962; 1: 162-71.

157.Kalow W. Pharmacogenetics - Heredity and Response to Drugs. Philadelphia: Sanders; 1962. p.1-

158.Killam KF. Drug action on the brain stem reticular formation. Pharmacol Rev 1962; 14: 175-223.

159.Klein DF, Fink M. Psychiatric reaction patterns to impramine. Am J Psychiatry 1962; 119: 432-8.

160.Leuner H. Die Experimentelle Psychose, Ihre Pharmakologie, Phenomenologie und Dynamik in Beziehung zur Person. Berlin: Springer; 1962.

161. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep 1962; 10: 799-812.

162.Prange AJ Jr, Lipton MA. Enhancement of imipramine mortality in hyperthyroid mice. Nature. 1962; 196: 588-9.

163.   Sargant W, Dally PJ. Treatment of anxiety states by antidepressant drugs. Br Med.J 1962; 1: 609.

164. Blackwell B. Hypertensive crisis due to MAOI. Lancet 1963; 2: 849-51.

165.Carlsson A, Lindqvist M.  Effect of chlorpromazine and haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain.  Acta Pharmacol Toxicol 1963; 20: 140-4.

166.Coppen A, Shaw DM, Farrell JP. Potentiation of the antidepressant effect of a monoamine oxidase inhibitor by tryptophan. Lancet  1963; 1: 79-81. 

167.Kelly HR, Fay JE, Laverty SG. Thioridazine hydrochloride (Mellaril): the effect on the electrocardiogram and a report on two fatalities with electrocardiographic abnormalities. J Can Med Assoc 1963; 89: 546-7.

168.Pare CMB.  Potentiation of monoamine oxidase inhibitors by tryptophan. Lancet 1963; 2: 527-8.

169.Prange AJ Jr, Lipton MA, Love GN. Diminution of imipramine mortality in hypothyroid mice. Nature. 1963; 197: 1212–3.

170.Anden NE, Carlsson A, Dahlström A, Fuxe K, Hillarp N-Ǻ. Demonstration and mapping of nigro-neostriatal dopamine neurons. Life Sciences 1964; 2: 623-30

171.Ban TA, St.Jean A. The effect of phenothiazines on the electrocardiogram. J Can Med. Assoc 1964; 91; 537-40.

172.Dahlström A, Fuxe K. Evidence for the existence of monoamine containing neurons in the central nervous sytem. I. Demonstration of monoamines in the cell bodies of brain stem neurons. Acta Physiol Scand 1964; 62 (Supplement 232): S1-S55.

173. Evans DAP, Davidson K, Pratt RTC. The influence on the effect of aceylator phenotype on the effect of treating depression with phenelzine, Clin Pharmacol Ther 1964; 6: 430-5.

174.Klein DF. Delineation of two drug-responsive anxiety syndromes. Psychopharmacologia 1964; 5: 397-408.

175.National Institute of Mental Health Psychopharmacology Service Center Collaborative Study Group. Phenothiazine treatment of acute schizophrenia: Effectiveness. Arch Gen Psychiatry 1964; 10: 244-61.

176.Wurtman RJ, Axelrod J, Fisher JA. Melatonin synthesis in the pineal gland: effect of light mediated by sympathetic nervous system. Science 1964; 143: 1328-9.

177.Agranoff BW, Davis RE, Brink JJ. Memory function in goldfish. Proc Natl Acad Sci USA 1965; 54: 788-9.

178.Bunney WE Jr, Davis JM. Norepinephrine in depressive reactions. Arch Gen Psychiatry. 1965; 3: 483-94.

179.Dahlström A, Fuxe K. Evidence for the existence`of monoamine neurons in the central nervous system. II. Experimentally-induced changes in the intraneuronal amine levels of bulbospinal neuron systems. Acta Physiol Scand 1965; 64 (Supplement 247): 1-36. 

180.  Dole VP, Nyswander ME. A medical treatment for diacetylmorphine (heroin) addiction. JAMA 1965; 193: 646-50.

181.Haase H-J. The presentation  and meaning of the psychomotor Parkinson syndrome  during long-term treatment. In: Haase H-J, Janssen PAJ. The Action of Neuroleptic Drugs. Chicago: Medical Year Book; 1965. p. 1-159.

182. Honigfeld G, Klett C. The Nurses Observation Scale for Inpatient Evaluation (NOSIE): A new scale for measuring improvement in chronic schizophrenia. J Clin Psychol 1965; 21: 65-71.

183.Klerman GL, Cole JO. Clinical pharmacology of imipramine and related antidepressant compounds. Pharmacological Reviews 1965; 17: 101-41.

184.Mechoulam R, Gaoni Y. A total synthesis of dl-Δ-1-tetrahydrocannabinol, the active component of hashish. J Amer Soc 1965; 87: 3273-4.

185.Schildkraut JJ. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry 1965; 122: 509-22.

186.Simpson GM, Amin M, Kunz E. Withdrawal effect of phenothiazines. Compr Psychiat 1965; 6: 347-51.

187.Spector S, Sjoersdma A, Udenfriend S. Blockade of endogenous norepinephrine synthesis by α-methyl-tyrosine, an inhibitor of tyrosine hydroxylase. Journal of Pharmacology 1965; 147: 86-95.

188.Anden NE, Dahlström A, Fuxe K, Larsson  K., Olson  L, Ungerstedt U. Ascending monoamine neurons to the telencephalon and diencephalons. Acta Physiologica Scandinavica 1966; 67: 31-26.

189.Barondes SH, Cohen HD. Puromycin effect on successive phases of memory storage. Science 1966; 151: 596-7.

190.Bridges PK, Jones MT. The diurnal rhythm of plasma cortisol concentration in depression. Brit J Psychiat 1966; 112: 1257-61.

191. Doig RJ, Mummery RV, Wills MR, Elkes A. Plasma cortisol levels in depression. Brit J Psychiatry 1966; 112: 1263-7.

192.Dole VP, Nyswander ME, Kreek MJ. Narcotic blockade a medical technique for stopping heroin use by addicts. Trans Assoc Am Phys 1966; 9: 122-36.

193.Domino EF, Chodoff P, Corssen G. Pharmacological effects of CI-581 (ketamine), a new dissociative anesthetic in man. Clin Pharmacol Ther 1966; 6: 279–91.

194. Wurtman RJ, Axelrod J. A`24-hour rhythm in the content of norepinephrine in the pineal and`salivary glands of the rat. Life Sci 1966; 5: 665-9.

195.Agranoff BW, Davis RE, Casola L, Lim R. Actinomycin D blocks formation of memory of shock-avoidance in goldfish. Science 1967; 158: 1600-1.

196.Baastrup PC, Schou M. Lithium as a prophylactic agent: Its effect against recurrent depression and manic depressive psychosis.  Arch Gen Psychiatry 1967; 16: 162-72.

197.Blackwell B, Marley E, Price J, Taylor D. Hypertensive interactions between monoamine oxidase inhibitors and foodstuffs. Br J Psychiatry 1967; 113: 349-65.

198. Curry SH, Brodie BB. Estimation of nanogram quantities of chlorpromazine (CPZ) in plasma using gas liquid chromatography (GLC) and an electron capture detector. Federation Proceedings 1967; 26: 761-2.   

199.Krieger DT, Krieger HP. Circadian pattern of plasma 17-hydroxycorticosteroids: Alteration by anticholinergic drugs. Science 1967; 155: 1421-2.

200.National Institute of Mental Health Pschopharmacology Research Branch Collaborative Study Group. Differences in clinical effects of three phenothiazines in “acute” schizophrenia. Dis Nerv Syst 1967; 28: 369-83.

201.Van Rossum JM.  The significance of dopamine receptor blockade` for the action of neuroleptic drugs. In: Brill H, Cole JO,  Deniker P, Hippius H,  Bradley PB, editors.  Neuropsychopharmacology. Proceedings of the Fifth International Congress of the Collegium Internationale Neuro-Psychopharmacologicum. Amsterdam: Excerpta Medica Foundation; 1967. p. 321-9.

202. Butler PWP, Besser GM. Pituitarry-adrenal function in severe depressive illness. Lancet 1968; 1: 1234-6

203.Carroll BJ, Martin FI, Davies B. Resistance to suppression by dexamethasone of plasma 11-OHCS levels in severe depressive illness. Brit Med J 1968; 3: 285-7.

204.Hartmann E. On the pharmacology of dreams and sleep (the D-state). J Nerv Ment Dis 1968; 146: 165–73.

205.Itil M, Shapiro DM, Fink M. Differentiation of psychotropic drugs: quantitative EEG analysis. Aggressologie 1968; 9: 267–80.

206.  Knoll J, Vizi ES, Somogyi G. Phenylisopropylmethylpropinylamine (E-250), a monoamine oxidase inhibitor antagonizing the effects of tyramine. Arzneimeittelforschung. 1968; 18: 109-12.

207.Shagass Ch. Pharmacology of evoked potentials in man.  In: Efron DH, Cole JO, Levine J, Wittenborn JR, editors. Psychopharmacology A Review of Progress. 1957–1967. Washington: Pu+blic Health Service Publications No 1836. Superintendent of Documents. Government Printing Office; 1968. p. 483–92.

208.Way EL, Leoh HH, Schen FH. Morphine tolerance, physical dependence and synthesis of brain 5-hydroxytryptamine. Science 1968; 162: 1290-2.

209. Angst J, Battegay R, Bente D, Berner P, Broeren  W, Cornu  F, Dick  P, Engelmeier  MP, Heimann  H, Helmchen  H, Hippius H,  Pöldinger W,  Schmidlin P, Schmitt W, Weis P.  The documentation system of the Association for Methodology and Documentation in Psychiatry (AMP). Arzneim Forsch 1969; 19:  399-405. (In German)

210.Ban TA. Psychopharmacology. Baltimore: Williams & Wilkins; 1969. p. 1-485.

211.Coyle JT, Snyder SH. Antiparkinsonian drugs: inhibition of dopamine uptake in the corpus striatum as a possible mechanism of action. Science 1969; 166; 899-901.

212.Coyle JT, Snyder SH.  Catecholamine uptake by synaptosomes in homogenates of rat brain: stereospecificity in different areas. J Pharmacol Exp Ther 1969; 170: 221-31.

213. Evans DAP, White TA. Human acetylation polymorphism.  J Lab Clin Med 1969; 63: 391-403.

214.Kalinowsky L, Hippius H. Pharmacological, Convulsive and Other Somatic Treatments in Psychiatry. New York: Grune & Stratton; 1969. p.1-

215.Klein DF, Davis JM.  Diagnosis and Drug Treatment of Psychiatric Disorders. Baltimore: Williams & Wilkins; 1969. p. 1-480.

216. Lapin JP, Oxenkrug GF. Intensification of the central serotonergic processes as a possible determinant of the thymoleptic effect. Lancet. 1969; 1: 32-9.

217.Prange AJ Jr, Wilson IC, Rabon AM, Lipton MA. Enhancement of imipramine antidepressant activity by thyroid hormone. Am J Psychiatry. 1969; 126: 457-69.

218.Curry SH, Marshall JH, Davis JM, Janowsky DS. Chlorpromazine plasma levels and effects. Arch Gen Psychiatry. 1970; 22: 289–96.

219.Guy W, Bonato R. Manual for the ECDEU Assessment Battery. Washington: DHEW Pub No (ADM) USGPO; 1970.

220.McLeod WR, Carroll BJ, Davies B. Hypothalamic dysfunction and antidepressant drugs. Brit Med J 1970; 2: 480-2.

221.Simpson GM, Angus JW A rating scale for extrapyramidal side effects. Acta Psychiatrica Scandinavica. 1970; 212 (Supplement):  11-9.

222.Squire R, Barondes SH. Actinomycin D: Effects on memory and differentiation after training. Nature 1970; 225: 649-50.

223.Van Praag HM, Korf J, Puite J. 5-Hydroxyindoleacetic acid levels in the cerebrospinal fluid of depressed patients treated with probenecid. Nature 1970; 225: 1259-60. 

224.Fawcett JA, Simopoulos V. Dextroamphetamine. Response as possible predictor of improvement with tricyclic antidepressants in depression. Arch Gen Psychiatry 1971; 25: 247-55.

225.Fernstrom JD, Wurtman RJ.  Brain serotonin content: physiological dependence on plasma tryptophan levels. Science 1971; 173: 149-52.

226.66Henn F, Hamberger A. Glial cell function: Uptake of transmitter substances. Proc Natl Acad Sci (USA) 1971; 68: 2686-90.

227.Jaffe JH, Senay EC. Methadone and 1-metadyl acetate use in the management of narcotic addicts. JAMA 1971; 216: 1303-5.

228.Kebabian JW, Greengard P. Dopamine sensitive adenyl cyclase: possible role in synaptic transmission. Science 1971; 174: 1346-9.

229. Sachar EJ, Finkelstein J, Hellman L. Growth hormone responses  in depressive illness. I. Response`to insulin tolerance test. Arch Gen Psychiatry 1971; 25: 263-9.

230.Van Praag HM, Korf J. Retarded depression and dopamine metabolism. Psychopharmacol 1971; 19: 199-203.

231.Weil-Malherbe, Szara S. The Biochemistry of Functional and Experimetal Psychoses. The Biochemistrty of Periodic Catatonia.  Springfield: Charles`C Thomas; 1971. p. 189- 203.

232.Bunney WE, Goodwin FK, Murphy DL, House KM, Gordon EK. The “switch process” in manic-depressive illness. II. Relationship to catecholamines, REM sleep and drugs. Arch Gen Psychiatry 1972; 27: 304-9.

233.Fernstrom JD, Wurtman RJ. Brain serotonin content: increase following ingestion of carbohydrate diet. Science 1972; 174: 1023-5.

234.Goodwin FK, Murphy DL, Dunner DL, Bunney WE. Lithium response in unipolar versus bipolar depression. Am J Psychiatry 1972; 129: 44-7.

235.Janowsky DS, el-Yousef MK, Davis JM, Sekerke HJ. A cholinergic-adrenergic hypothesis of mania and depression. Lancet 1972; 2: 632-5.

236.Prange AJ Jr, Wilson IC, Lara PP, Alltop LB, Breese GR. Effects of thyrotropin releasing hormone in depression. Lancet. 1972; 2: 999-1002.

237.Cooper TB, Bergner PE, Simpson GM. The 24-hour serum lithium level as a prognosticator of dosage requirement. Am J Psychiatry 1973; 30: 601-3.

238.Janowsky DS, el-Yousef MK, Davis JM, Sekerke HJ. Provocation of schizophrenic symptoms by intravenous administration of methylphenidate. Arch Gen Psychiatry 1973; 28: 185-9.

239.Okuma T, Kishimoto A, Inoe K, Matsumoto  H, Ogura A, Matsushita T, Nakao T, Ogura C. Antimanic and prophylactic  effects of carbamazepine  (Tegretol)  on manic depressive psychosis: A preliminary report.  Folia Psychiatr Neurol Jpn 1973; 27: 283-97.

240.Pert C, Snyder SH. Opiate receptor: demonstration in nervous issue. Science 1973; 179: 1011-4.

241.Robinson DS, Nies A, Ravaris CL, Lamborn KR. The monoamine oxidase inhibitor, phenelzine, in the treatment of depressive-anxiety states; a controlled clinical trial. Arch Gen Psychiatry. 1973; 29: 407-413.

242.Van Praag HM, Korf J, Schut T. Cerebral monoamines and depression. An investigation with the probenecid technique Arch G+en Psychiatry1973; 28:827-31.

243.Angrist B, Sathananthan G, Wilk S, Gershon S. Amphetamine psychosis: Behavioral and biochemical aspects. J Psychiatr Res 1974; 11: 13-23.

244.Ban TA. Depression and the Tricyclic Antidepressants. Montreal: Ronalds Federated; 1974. p. 1-74.

245.Joynt RJ. The use of bromides in epilepsy. Am J Diseases of Children 1974; 128: 362–3.

246.Winokur A, Utiger RD. Thyrotropin releasing hormone: regional distribution in the rat brain. Science 1974; 185: 265-6.

247.  Langer SZ. Presynaptic regulation of catecholamine release. Biochem Pharmacol 1974; 23: 1793-800.

248.Stein L, Belluzzi JD, Ritter S, Wise D. Self-stimulation, reward pathways -  norepinephrine vs dopamine . J Psychiatr Res 1974; 11: 115–24.

249.Davis JM. Overview: Maintenance therapy in psychiatry. I Schizophrenia. Am J Psychiatry 1975; 132: 1237-45

250.. Idanpään-Heikkila J, Alhave E, Olkimora M, Palva J. Clozapine and agranulocytosis.  Lancet 1975; 1: 611-2.

251.Iversen SD, Iversen LL. Behavioral Pharmacology. Oxford: Oxford University Press; 1975. p. 1-303.

252.Kaufman S. Holtzman NA, Milstein S, Butler IJ, Krumholz A. Phenylketonuria due to deficiency of dihydropteridine release. N Eng J Med 1975; 293: 783-90.

253. Seeman P, Chau-Wong M, Tedesco J, Won K. Brain receptors for antipsychotic drugs and dopamine direct binding assays. Proc Natl Acad Sci USA. 1975; 72: 4376- 80.

254.Shopsin B, Gershon S, Goldstein M, Friedman E, Wilk S. Use of synthesis inhibitors in defining Commun 1975; 1: 239–49.

255.Snyder S, Creese L, Burt  DR. The brain’s dopamine receptor: labeling with [3H] dopamine and [3H] haloperidol. Psychopharmacol Commun 1975; 1: 663-73.

256.Vetulani J, Sulser F. Action of various antidepressant treatments reduces the reactivity of the noradrenergic cyclic AMP-generating system in limbic forebrain. Nature 1975; 257: 495-6.

257.Burt DR, Creese I, Snyder SH. Properties of [3H] - haloperidol and [3H] - dopamine binding associated with dopamine receptors in calf brain. Mol Parmacol 1976; 12: 800-12.

258.Carroll BJ, Curtis GC. Neuroendocrine identification of depressed patients. Aust NZJ Psychiat 1976; 10: 13-20.

259.Carroll BJ, Curtis GC, Mendels J. Neuroendocrine regulation in depression. I. Limbic system-adrenocortical dysfunction. Arch Gen Psychiatry 1976; 33: 1039-33.

260.Carroll BJ, Curtis GC, Mendels J. Neuroendocrine regulation of depression. II. Discrimination of depressed and non-depressed paients. Arch Gen Psychiatry 1976; 33: 1051-8

261.Davies P, Maloney AJF. Selective loss of central cholinergic neurons in Alzheimer’s disease. Lancet 1976; 2: 1403-4.

262.Davis JM. Overview: Maintenance therapy in psychiatry. II. Affective disorders. Am J Psychiat 1976; 133: 1-13.

263.Fieve RR, Kumbaracki T, Dunner DL. Lithium prophylaxis of depression in bipolar I, bipolar II and unipolar patients. Am J Psychiatry 1976; 133: 925-30. 

264.Guy W. Manual for the ECDEU Assessment Battery. Revised.  Washington: DHEW Pub No (ADM) USGPO; 1976.

265.Johnstone EC. The relationship between acetylator status and inhibition of monoamine oxidase, excretion of free drug and antidepressant response in depressed patients on phenelzine. Psychopharmacologia 1976; 45: 489-94.

266.Pert C, Kuhar MJ, Snyder SH. Opiate receptor: localization in rat brain. Proc Natl Acad Sci USA 1976; 73: 3729-33.

267.Seeman P, Lee T, Chau-Wong M, Wong K. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature (London) 1976; .261: 717-9.

268.Shopsin B, Friedman E, Gershon S. Parachlorophenylalanine reversal of tranylcypromine  effects in depressed patients. Arch Gen Psychiatry  1976; 33: 811-9.

269.Snyder SH. The dopamine hypothesis of schizophrenia. Focus on the dopamine receptor. Am J Psychiatry 1976; 133: 140-4.

270.Richelson E, Divinetz-Romero S. Blockade by psychotropic drugs of the muscarinic acetylcholine receptor in cultured nerve cells. Biol Psychiatry 1977; 12::771–85.

271.Sokolov L, Reivich M, Kennedy C, Des Rosiers MH, Patlak CR, Pettigrew KD, Sakurada O, Shinohara M. The [14C] deoxyglucose method for the measurement of local cerebral glcose utilization. Theory, procedure, and normal values in the conscious and anesthetized albino rat.  J Neurochem 1977; 2: 897-916,

272.Stahl SM. The human platelet: a diagnostic research tool for the study of biogenic amines in psychiatric and neurologic disorders. Arch Gen Psychiatry 1977;  34: 509-16.

273.Blaine JD, Renault P, Levine GL, Whysner JA. Clinical use of LAAM. Annals of the New York Academy of Sciences 1978; 311: 214-31

274.Braestrup C, Squires RF. Brain specific benzodiazepine receptors. The British Journal of Psychiatry 1978; 133: 249-6

275.0.6Chouinard G, Jones BD, Annable L. Neuroleptic-induced supersensitivity psychosis. Am J Psychiatry 1978; 135: 1409-10.

276. Davis KL, Mohr RC, Tinklenberg JR, et al. Physostigmine. Improvement of long-term memory process in normal humans. Science 1978; 201:  272-4.

277.  De Montigny C, Aghajanian GK. Tricyclic antidepressants: long-term treatment increases responsivity of rat forebrain neurons to serotonin. Science  1978; 20: 1302-6.

278.Gold MS, Redmond DE, Kleber HD. Cloinidine in opiate withdrawal. Lancet 1978; 11: 599- 602.

279.Richelson E. Tricyclic antidepressants block histamine H1 receptors of mouse neuroblastoma cells. Nature 1978; 274:176-7.

280.Simpson GM, Lee JH, Zoubok B, Gardos G.  A rating scale for tardive dyskinesia. Psychopharmacologia 1978; 64: 171-9.

281.Goldberg SC, Halmi KA, Eckert ED. Cyproheptadine in anorexia nervosa. British Journal of Psychiatry 1979; 134: 167-70.

282.Amerian Psychiatric Association. Diagnostic and Statistical Manual of Psychiatric Disorders. Third Edition. (DSM-III). Washington: American Psychiatric Association; 1980. p. 1-494.

283.Ballanger JC, Post RM. Carbamazepine in manic-depressive illness. A new treatment . Am J Psychiatry 1980; 137: 782-90.

284.Ban TA. Psychopharmacology for the Aged. Basel: Karger; 1980. p. 1-215.

285.Conners CK. Food Additives and Hyperactive Children. New York: Plenum Press; 1980. p. 1-

286.Langer SZ, Moret C, Raisman R, Dubokovitch ML, Briley M. High affinity [3H]-imipramine binding in rat hypothalamus associated with uptake of serotonin but not of norepinephrne. Science 1980; 210: 1133-5.

287.Langer SZ. Presynaptic regulation of the release of catecholamines. Pharmacol Reviews 1980; 32: 337-62. 

288.Lewy AJ, Wehr TA, Goodwin FK, Newsome DA, Markey SP. Light suppresses melatonin secretion in human. Science 1980; 210: 1257-9.

289.Matussek N, Ackenheil M, Hippius H, Mueller F, Schröder H-T, Schultes H, Wasilewski B. Effect of clonidine in growth hormone release in psychiatric patients and controls. Psychiatry Research 1980: 2: 25-36.

290.Nemeroff CB. Neurotensin perchance an endogenous neuroleptic. Biol Psychiatry 1980; 15: 283-302.

291.Paul SM, Rehavi M, Skolnick P, Goodwin FK. Demonstration of high affinity binding sites for [3-H] imipramine  in human platelets. Lif Sci 1980; 26: 953-9.

292.Ban TA. Psychopharmacology of Depression. Basel: Karger; 1981. p. 1-127.

293.Blackshear MA, Steranka LR, Sanders-Bush E. Multiple serotonin receptors: regional distribution  and effect of raphe lesion. Eur J Pharmacol 1981; 76: 325-34.

294.Klein DF. Anxiety re-conceptualized; Gleaming from pharmacological dissection - early experience with imipramine and anxiety. In: Klein  DF, Rabkin JG, editors. Anxiety: New Research & Changing Concepts. New York: Raven Press; 1981. p. 235-62.

295.Davis KL, Mohr RC. Enhancement of memory processes in Alzheimer’s disease with multiple-dose intravenous physostigmine. Am J Psychiatry 1982; 139: 1421-

296.4.   Reisberg B, Ferris SH, de Leon MJ, Crook T. The Global Deterioration Scale (GDS). An instrument for the assessment of primary degenerative dementia. American Journl of Psychiatry 1982; 139: 1136-9.

297.Fuxe K, Agnati LF, Benfenati  F, Celani MF, Zini  I, Zoli  M, Mutt V.  Evidence for the existence of receptor-receptor interactions in the central nervous system. Studies on the regulation  of the monoamine receptors by peptides. J Neurol Transmission 1983; 18: 115-79.

298.Reisberg B, Schneck MK, Ferris SH, Schwartz GE, de Leon MJ. The Brif Cognitive Rating Scale. Findings in primary degenerative dementia (PDD). Psychopharmacology Bulletin 1983; 19: 47-50.

299.Bloom FE. Neuropeptides and other mediators in the central nervous system. J Immunol 1985; 135: 743–5

300..Fink M. Pharmacoelectroencephalography: A note on its history. Neuropsychobiology 1985; 12: 173-8.

301.Potter WZ, Scheinin M, Goden RN, Rudorfer MV, Cowdry RW, Calil HM, Ross RJ, Linnoila M. Selective antidepressants and cerebrospinal fluid: Lack of specificity on norepinephine and serotonin metabolites. Arch Gen Psychiatry 1985; 47: 1171-77.

302.Agnati LF, Fuxe K, Zoli M, Zini I, Toffano G, Ferraguti F. A correlation analysis of regional distribution of central enkephalin and ß-endorphin immunoreactive terminals and of opiate receptor in adult and old male rats. Evidence of the existence of two main types of communications in the central nervous system: The volume transmission and the wiring transmission. Acta Physiol Scand 1986; 128: 201-7

303..Caldwell JD, Prange AJ, Pedersen CA. Oxytocin facilitates the sexual receptivity of estrogen-treated female rats. Neuropeptides 1986; 7: 175-89.

304.Levine J, Schooler NR. A technique for the systematic assessment of side effects in clinical trals. Psychopharmacology Bulletin 1986; 22: 343-81.

305. American Psychiatric Association. Diagnostic and Statistical Manual of Psychiatric Disorders. Third Edition. Revised. (DSM-III-R.) Washington: American Psychiatric Association; 1987. p. 1-567.

306.Ban TA. Prolegomenon to the clinical prerequisite: Psychopharmacology and the classification of mental disorders. Progress in Neuro-Psychopharmacology and Biological Psychiatry 1987; 11: 527-80.

307.Petho B, Ban TA. DCR Budapest-Nashville in the Diagnosis and Classification of Functional Psychoses. Psychopathology 1988; 21: 153-240.

308.Ban TA. CODE DD Composite Diagnostic Evaluation of Depressive Disorders. Brentwood: JM Productions; 1989. p. 1-236.

309.Knoll J, Dallo J, Yen TT. Striatal dopamine, sexual activity, life span. Longevity  of rats treated with  (-) deprenyl. Life Sci 1989; 45: 525-31.

310.Meltzer HY, Matsubara S, Lee JC. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D1, D2 and serotonin2 pk1 values. J Exp Ther 1989; 251: 238-48.

311.Rapoport J. The neurobiology of obsessive-compulsive disorder. JAMA 1989; 260: 2888-90.

312.Ban TA. Clinical pharmacology and Leonhard’s classification of endogenous psychoses. Psychopathology 1990; 23: 331-8.

313.Burnett AL, Lowenstein CJ, Bradt DS, Snyder SH. Nitric oxide a physiologic mediator of penile erection. Science 1992; 257: 41-2

314.Damsma G, Pfaus JG, Wenkstern D, Phillips AG, Fibiger HC. Sexual  behavior increases  dopamine transmission  in the striatum  of male rats: comparison with novelty of locomotion. Behavioral Neursci 1992; 106: 181-91.

315. De Montigny C, Blier P. Potentiation of 5-HT neurotransmission by short-term lithium: in vivo electrophysiological studies. Clinical Neuropharmacology 1992; 15 (Supplement): 610-11

316.Lewy AJ, Ahmad S, Jackson JML, Sack RL. Melatonin shifts circadian rhythm  according to a phase response curve. Chronobiol 1992; 9: 390-92.

317.Snyder S. Nitric oxide: first of a new class of neurotransmitters. Science 1992; 257: 494-6.

318.Davis JM, Wang Z, Janicak PG. A Quantitative analysis of clinical drug trials for the treatment of affective disorders. Psychopharmacol Bull  1993;  175-81

319.Papp LA, Klein DF, Gorman JM.. Carbon dioxide hypersensitivity, hyperventilation and panic disorder. Am J Psychiatry 1993; 150: 1149-57.

320.Quitkin FM, Stewart JW, McGrath PJ, Tricamo E, Rabkin JG, Ocepek-Welikson K, Nunes E, Harrison W, Klein DF. Atypical depression: a subgroup of depressives with better response to MAOI than to tricyclic antidepressants or placebo. Br J Psychiatry 1993; 21: 30-34.

321.American Psychiatric Association. Diagnostic and Statistical Manual of Psychiatric Disorders. Fourth Edition. (DSM-IV.) Washington: American Psychiatric Association; 1994. p. 1-886.

322.Healy D. The Antidepressant Era. Cambridge: Harvard University Press; 1997. p. 1-317.

323.Gottschalk LA. The application of computerized measurement of the content analysis of the natural language to the assessment of the effects of psychoactive drugs. Methods and Findings in Experimental and Clinical Pharmacology 1999; 21: 133-8

324.  Uhlenhuth EH, Balter MB, Ban TA, Yang K. International study of expert judgment on therapeutic use of benzodiazepines and other therapeutic medications: IV. Therapeutic dose dependence and abuse liability of benzodiazepines  in the long-term treatment of anxiety disorders. J Clin Psychopharmacol 1999; 19: 2-29

325..  Berman RM, Capiello A, Anand A, Oren DA, Heninger GR, Charney DS, Krystal JH. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000; 47: 351-4.

326.Ban TA. Pharmacotherapy of mental illness. A historical analysis. Prog Neuropsychopharmacol & Biol Psychiatry 2001; 25: 709-27.

327.Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Kiefe RSE, Davis SM, Davis CI, Lebowitz GD, Severe J, Hsiao JK, for the Clinical Antipsychotic Trials of the Intervention Effectiveness Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia The New England Journal of Medicine 2005; 353: 1209-23.

328.Szuba MP, Amsterdam JD, Fernando AT, Whybrow PC, Winokur A. Rapid antidepressant response after nocturnal TRH administration in patients with bipolar I and bipolar II disorders with major depression. J Clin Psychopharmacol 2005; 25: 325-30

329..Ban TA. Academic psychiatry and the pharmaceutical industry. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30: 429–41.

330.Ban T. The role of serendipity in drug discovery. Discoveries in Clinical Neuroscience 2006; 8: 335-44.

331.Coyle JT. Glutamate and schizophrenia: Beyond the dopamine hypothesis. Cellular and Molecular Neurobiology 2006; 26: 365-84.

332.Lewy AJ, Emens J, Jackman A, Yuhas K. Circadian uses of melatonin in human. Chronobiology International 2006; 23: 403-12.

333.Ban TA. Towards a clinical methodology for neuropsychopharmacological research. Neuropsychopharmacologia Hungarica 2007; 9: 81-90.

334.Janowsky DS. Scopolamine as an antidepressant agent: theoretical and treatment considerations. Curr Pschiat Rep 2007; 9: 47-8.

León S. Morra

October 6, 2016